Genspera Inc  

(Public, OTCMKTS:GNSZ)   Watch this stock  
Find more results for Genspera, Inc.�
-0.002 (-1.92%)
Jul 25 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.13 - 0.13
52 week 0.10 - 0.94
Open 0.13
Vol / Avg. 9,200.00/23,601.00
Mkt cap 5.32M
P/E     -
Div/yield     -
EPS -0.12
Shares 41.76M
Beta 0.42
Inst. own 10%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -88.41% -221.82%
Return on average equity - -
Employees 2 -
CDP Score - -


2511 N Loop 1604 W Suite 204 (3RD Floor
SAN ANTONIO, TX 78258-4633
United States - Map
+1-210-4798112 (Phone)
+1-210-4798113 (Fax)

Website links


GenSpera, Inc. (GenSpera) is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, renal and other cancers. Its technology platform combines a plant-derived cytotoxin with a prodrug delivery system that targets the release of the drug within the tumor. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Its lead drug candidate, mipsagargin, is activated by the enzyme prostate specific membrane antigen (PSMA), which is found in prostate epithelial cells in the normal prostate, in prostate cancer cells, and in vascular endothelial cells (blood vessels) found in solid tumors. G-115 and G-114 are activated by the enzyme prostate specific antigen (PSA). G-301 is activated by the enzyme human glandular kallikrein 2 (hK2).

Officers and directors

Peter E. Grebow Ph.D. interim Chairman of the Board
Age: 68
Russell Richerson Ph.D. Chief Operating Officer, Secretary, interim Principal Executive and Accounting Officer
Age: 64
Bo Jesper Hansen M.D., Ph.D. Independent Director
Age: 58
Scott V. Ogilvie Independent Director
Age: 61